Zydus receives final approval for Exemestane Tablets from the USFDA

Deepthi | Myequity news | Date : 05-10-2018 12:00:00 IST

Zydus Cadila has received the final approval from the USFDA to market Exemestane Tablets, (US RLD AROMASIN Tablets), 25mg. It will be manufactured at the group‘s formulations manufacturing facility at SEZ, Ahmedabad. The estimated sale for Exemestane Tablets is $68.6 million.

About Zydus Cadila:

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally.


More from Myequity